Organogenesis Holdings Inc. (NASDAQ:ORGO) finished Thursday with a subtraction of -$0.54 to close at $12.51, a downside of -4.14 percent. An average of 1,576,880 shares of common stock have been traded in the last five days. There was a fall of -$1.73 in the past week. The last 20 days have seen an average of 1,353,805 shares traded, while the 50-day average volume stands at 948,230.
ORGO stock has decreased by -21.42% in the last month. The company shares reached their 1-month lowest point of $12.09 on 10/07/21. With the stock rallying to its 52-week high on 04/09/21, shares of the company touched a low of $3.45 and a high of $24.34 in 52 weeks. In spite of this, the price is down -48.60% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
81 days have passed since Organogenesis Holdings Inc. (ORGO) last reported insider trading activity. Gillheeney Gary S., who is President and CEO, most recently acquired $160,237 shares at $14.02 per share on Jul 19. In this transaction, the insider spent $2,246,523. President and CEO, Gillheeney Gary S., disposed of 139,763 shares at a price of $14.74 on Jul 16. The insider now owns more than $2,059,820 worth of shares. Prior to that, 10% Owner ERANI ALBERT went on to Sale 150,000 shares at $15.31 each on Jun 09. An amount of $2,296,500 was transacted.
Organogenesis Holdings Inc. (ORGO) has a trailing price-to-earnings (P/E) ratio of 22.22, which compares with the 23.00 for the broader industry and 32.11 for the sector. This means investors are optimistic about the stock’s future prospects. In the last five years, Organogenesis Holdings Inc.’s PE ratio has ranged between 162.00 and 22.34. The stock’s beta is 1.53. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.91, the price-to-book (PB) ratio at 8.94, and the price-to-cash flow ratio at 66.28.
The quick ratio of Organogenesis Holdings Inc. for the three months ended June 29 was 2.10, and the current ratio was 2.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.32 and a total debt to equity ratio of 0.47 For the recent quarter ending June 29. On the profitability front, the trailing 12-month gross margin is 76.00% against a 5-year average of 68.8%. Organogenesis Holdings Inc.’s EBITDA margin for the year ending June 29 is 10.31%, while its operating margin for the same period stands at 18.90%. Its gross profit as reported stood at $250.98 million compared to revenue of $338.3 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Organogenesis Holdings Inc.’s return on assets was 23.10%, compared to -14.1% over the last five years. In the past year, the return on investment has been 12.60%, and the 5-year average is -15.8%. Meanwhile, the return on equity (ROE) for the past 12 months has been 51.20% and the 5-year average holds at -83.3%. For the broader industry, ROE averaged -15.50 over the past year.
The analyst consensus anticipated Organogenesis Holdings Inc.’s latest quarter earnings to come in at $0.07 per share, but it turned out to be $0.15, a 114.30% surprise. For the recent quarter, EBITDA amounted to $27.33 million. Shareholders own equity worth $128.58 million.
From a technical analysis perspective, let’s take a brief look at Organogenesis Holdings Inc. (ORGO) price momentum. RSI 9-day as of the close on 07 October was 26.16%, suggesting the stock is oversold, with historical volatility in this time frame at 33.75%.
As of today, ORGO’s price is $13.11 -12.15% or -$1.73 from its 5-day moving average. ORGO is currently trading -23.86% lower than its 20-day SMA and -26.54% lower than its 100-day SMA. However, the stock’s current price level is -18.34% below the SMA50 and +103.08% above the SMA200.
The stochastic %K and %D were 8.41% and 7.17%, respectively, and the average true range (ATR) was 0.81. With the 14-day stochastic at 8.55% and the average true range at 0.85, the RSI (14) stands at 32.52%. The stock has reached -0.88 on the 9-day MACD Oscillator while the 14-day reading was at -1.60.
SVB Leerink launched coverage on Organogenesis Holdings Inc. (NASDAQ: ORGO) in its analyst report released on January 10, 2020. The firm assigned the stock a an Outperform rating.The consensus rating for Organogenesis Holdings Inc. (ORGO) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ORGO, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.
What is ORGO’s price target for the next 12 months?
Analysts predict a range of price targets between $25.00 and $29.00, with a median target of $26.50. Taking a look at these predictions, the average price target given by analysts for Organogenesis Holdings Inc. (ORGO) stock is $26.75.